What METiS Therapeutics does

METiS Therapeutics is an AI-empowered drug discovery and delivery company that develops lipid nanoparticle (LNP) technologies and therapeutic candidates for oncology, immunology, and metabolic diseases. Its core technology combines Artificial Intelligence, Machine Learning, and Molecular Dynamics with high-throughput in vivo screening to discover organ-targeting LNPs, enabling targeted delivery of small molecules, RNA, and gene therapies. The company operates a proprietary AI platform branded NanoForge, complemented by specialized delivery systems AiLNP, AiRNA, and AiTEM. Lead candidate MTS-004 became China's first AI-enabled formulation drug to complete Phase III clinical trials, and the pipeline includes MTS-105 and MTS-107 in oncology as well as a preclinical heart-targeted LNP program demonstrating near-complete cardiomyocyte delivery.

The company operates a B2B, partnership-driven business model targeting pharmaceutical and biotech companies. Revenue is generated primarily through out-licensing AI-discovered candidates and nanoparticle technologies, with MTS-004 outlicensed in September 2025 for up to RMB 1.845 billion in potential milestones. Upfront partnership payments drove RMB 105 million (~$14.5 million) in 2025 revenue at a 98.2% gross margin, against a net loss of CNY 391.8 million. Strategic pharma relationships include the Roche Accelerator program (joined May 2022), a license agreement with Evonpoint Biosciences (January 2023), and a Pan-RAF inhibitor license with Voronoi (September 2022).

METiS Therapeutics Inc., the Delaware-incorporated US parent headquartered at 101 Cambridgepark Drive, Cambridge, MA, remains a private company. Its subsidiary METiS TechBio Co. Ltd. completed an IPO on the Hong Kong Stock Exchange (SEHK:7666) in May 2026, raising approximately HKD 2.11 billion (~$270 million) in the largest healthcare IPO in Hong Kong in 2026, with shares surging up to 185% on debut and the offering oversubscribed by more than 6,900 times. The company has raised over $300 million across multiple rounds since its 2021 founding, from investors including Sequoia Capital China, 5Y Capital, Lightspeed China Partners, CICC Capital, China Life Insurance, and HongShan, with the IPO attracting BlackRock, UBS, Mirae Asset, and ORIX as cornerstone investors.

Name

METiS Therapeutics

Legal name

METiS Therapeutics Inc.

Website

https://metistx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

METiS Therapeutics is an AI-empowered drug discovery and delivery company developing lipid nanoparticle technologies and therapeutic candidates in oncology, immunology, and metabolic diseases, serving pharmaceutical partners through licensing and co-development deals such as Roche, Evopoint, and Voronoi.

Ownership category

akta.pro rank

Product category

AI-Enabled Drug Delivery Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Sample / Biorepository & Biobank Informatics (Chain-of-Custody) (HLAGAJAH)

Keywords

• AI drug discovery
• Lipid nanoparticle delivery
• RNA therapeutics platform
• Nucleic acid delivery
• Biopharma licensing

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Licensing and Partnership Revenue: The company generates revenue through out-licensing its AI-developed drug candidates and nanoparticle technologies to pharmaceutical partners. Lead candidate MTS-004 was outlicensed in September 2025 with potential total milestone payments of up to RMB 1.845 billion.
2. R&D Partnerships: Revenue from upfront partnership payments, as evidenced by RMB 105 million revenue in 2025 from upfront partnership payments for MTS-004.
3. Product Development: The company reports revenue from its pipeline products, with HK$105.0 million (RMB 105 million) in revenue recorded in 2025, though the company is currently loss-making with net loss of CN¥391.836 million.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

METiS Therapeutics leverages Artificial Intelligence, Machine Learning, and Molecular Dynamics to discover and develop lipid nanoparticle (LNP) drug delivery systems and novel therapeutics across small molecule, biologics, and advanced nucleic acid spaces. The company uses its NanoForge AI platform with high-throughput in vivo screening to discover organ-targeting LNPs, and develops a pipeline of drug candidates (e.g., MTS-004) which it out-licenses to pharmaceutical partners.

Product overview

METiS Therapeutics operates as an AI-empowered drug delivery company with a platform-plus-pipeline architecture. The core technology is the NanoForge AI platform, complemented by specialized delivery systems (AiLNP, AiRNA, AiTEM) that enable targeted nanodelivery of therapeutics. The company develops drug candidates across three therapeutic areas: oncology, immunology, and metabolic diseases. The pipeline includes lead candidate MTS-004 (completed Phase III), as well as MTS-105 and MTS-107 in oncology, with a heart-targeted LNP program in preclinical development. The company went public on the Hong Kong Stock Exchange in May 2026, becoming the world's first publicly listed AI-powered drug delivery company.

Differentiator

Problem solved

Functional benefit

Brands

• NanoForge: AI nanodelivery platform used to drive the company's product pipeline across oncology, immunology, and metabolic diseases
• AiLNP
• AiRNA
• AiTEM

Products and services

• NanoForge AI-powered nanodelivery platform that drives METiS's drug discovery pipeline, enabling rapid development of nanoparticle-based therapeutics across oncology, immunology, and metabolic diseases. Shortens drug development timelines from years to 18 months.
• AiLNP AI-enhanced Lipid Nanoparticle delivery system designed for targeted genetic medicine and mRNA therapeutics, enabling organ-specific delivery of nucleic acid payloads.
• AiRNA AI-powered RNA delivery platform for nucleic acid therapeutics, enabling precise targeting and delivery of RNA-based treatments.
• AiTEM AI-enabled targeted delivery system for enhancing therapeutic payload delivery to specific tissues and organs.
• MTS-004 Lead drug candidate and China's first AI-enabled formulation drug to complete Phase III clinical trials (October 2024). Outlicensed in September 2025 with potential total milestone payments of up to RMB 1.845 billion; NDA submission planned for later 2026.
• MTS-105 Oncology candidate demonstrating mRNA-based cancer therapeutics using targeted lipid nanoparticle delivery systems to activate antitumor immunity. Published in Nature Communications.
• MTS-107 Oncology candidate showcasing targeted LNP delivery for mRNA-based cancer therapeutics and immune activation. Published in Journal for ImmunoTherapy of Cancer.
• Heart-Targeted LNP Program Preclinical heart-targeted lipid nanoparticle program demonstrating near-complete (~100%) delivery and gene editing in cardiomyocytes following intravenous administration. Data selected for presentation at CRS 2026.

Quantifiable outcome

• Near-complete (~100%) delivery and gene editing in cardiomyocytes following intravenous administration
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• Evopoint BiosciencesflagshipOEM/ Whitelabel/ Licensing Partner · 6 January 2023METiS announced a license agreement with Evopoint Biosciences for the licensing of its AI-developed nanoparticle technology or drug candidates.
• VoronoicoreOEM/ Whitelabel/ Licensing Partner · 13 September 2022METiS announced a Pan-RAF Inhibitor license agreement with Voronoi, licensing out an AI-developed drug candidate for cancer treatment.
• Roche AcceleratorcoreStrategic or Co-development Partner · 18 May 2022METiS joined the Roche Accelerator program in May 2022, indicating a strategic partnership with one of the world's largest pharmaceutical companies for development and potential commercialization of AI-developed therapeutics.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Acuitas Therapeutics: Acuitas specializes in lipid nanoparticle (LNP) delivery technology for nucleic acid therapeutics, including mRNA vaccines and gene therapies. It is a leading LNP platform licensor and the most direct peer to METiS's AiLNP and AiRNA delivery systems.
• Arcturus Therapeutics: Arcturus develops RNA medicines using proprietary LNP delivery technology and AI-augmented design approaches, with clinical programs in infectious disease and rare diseases. Closely comparable to METiS in its combination of LNP delivery plus nucleic acid pipeline.
• Insitro: Insitro applies machine learning to drug discovery and development across multiple therapeutic areas with a platform-plus-pipeline model. Directly comparable to METiS's NanoForge AI platform approach to therapeutic discovery and optimization.
• Recursion Pharmaceuticals: Recursion uses AI and high-throughput biology to discover and develop therapeutics at scale. Its platform-plus-pipeline architecture and AI-driven drug discovery approach mirror METiS's strategic positioning.
• Generate Biomedicines: Generate Biomedicines uses generative AI to design novel protein therapeutics across multiple modalities. Closely aligned with METiS's AI-first approach to therapeutic design and platform extensibility across biologics and nucleic acids.
• Schrödinger: Schrödinger operates a physics-based computational platform for drug discovery and collaborates with major pharma on AI-enabled therapeutics. Comparable as an AI drug discovery platform serving pharma partners through licensing and co-development.
• AbCellera: AbCellera uses AI/ML-driven antibody discovery and engineering to generate biologic therapeutic candidates. Comparable as an AI-enabled biotech with a platform-plus-pipeline model targeting pharma partnerships.
• Lantern Pharma: Lantern Pharma applies AI and machine learning to oncology drug development, focusing on identifying and advancing targeted therapeutics. Comparable as an AI-driven biotech with clinical-stage pipeline assets.

Broad incumbents

• Moderna: Moderna is a leading mRNA therapeutics company with proprietary LNP delivery technology and multiple commercial products. Serves as a broad incumbent in the LNP/nucleic acid delivery space where METiS competes.
• BioNTech: BioNTech is a leading immunotherapy company with proprietary LNP delivery systems and commercial mRNA products. A broad incumbent competitor in nucleic acid delivery and AI-enabled therapeutic development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MetisTx
• LinkedInlinkedin.com/company/metis-pharmaceuticals-inc/about

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about METiS Therapeutics